Vantage logo

Pressure on Abbvie's pipeline grows

Abbvie will need more than Skyrizi and upadacitinib to fill a Humira-shaped hole, and there are a few early-stage candidates it reckons could fit the bill.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.